Home » The Viewpoint » Page 50

Category Archives: The Viewpoint

Ops Page for Editorials, and …Opinions

The Futile Quest of Proofing a Negative in the Presence of Overwhelming Absence of Harm

Posted on by — No Comments ↓

The cartilage damage caused by fluoroquinolones in juvenile beagle dogs is not subtle:  blister formation and erosions occur in a dose-dependent fashion resulting in reversible cartilage damage.  These lesions can be seen not just histologically but even macroscopically.  The animals are unable to walk as weight-bearing joints are predominantly affected.  Continue reading The Futile Quest of Proofing a Negative in the Presence of Overwhelming Absence of Harm→

Following The Publication Trail of Two RSV Drugs

Posted on by — 2 Comments ↓

In a publication from 2007, investigators from Arrow Pharmaceuticals told us that A-60444 (later renamed to RSV-604) was already in Phase 2.  Since then, it has been very quiet about this compound.  Some have suggested that Novartis has stopped development [1], an impression supported by the fact that the drug is Continue reading Following The Publication Trail of Two RSV Drugs→

Not So Boring:  Boron-Containing Antibiotics Create a Stir

Posted on by — No Comments ↓

Why are there so few boron-containing drugs on the market?  The cancer drug bortezumib (Velcade®) may be the only better-known drug on the market with a boron atom in its structure.[1]  Among antibiotics, there is Kerydin™ (tavaborole), an approved topical solution for the treatment of onychomycosis caused by Trichophyton but Continue reading Not So Boring:  Boron-Containing Antibiotics Create a Stir→